CHMP identificerede, at den nedsatte immunogenicitet af den HepB- komponent, som er frigivet af indehaveren af markedsføringstilladelsen, skyldes variabiliteten i produktionsprocessen for denne komponent.
The CHMP identified that the decreased immunogeniticy of the HepB component released by the MAH seems to be due to variability in the production process for this component.